Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults

  • Abril Gil, Maria del Mar
  • Albert Bayo, Merce
  • Exposito Fernandez, Elba
  • Gonzalez Castro, Ana Maria
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Alonso Cotoner, Carmen
  • Ganda Mall, John-Peter
Chronic diarrhea; Mucoprotectans; Mucus, Diarrea crónica; Mucoprotectores; Moco, Diarrea crònica, Mucoprotectors; Moc, Chronic diarrhea is a frequent presenting symptom, both in primary care medicine and in specialized gastroenterology units. It is estimated that more than 5% of the global population suffers from chronic diarrhea. and that about 40% of these subjects are older than 60 years. The clinician is frequently faced with the need to decide which is the best therapeutic approach for these patients. While the origin of chronic diarrhea is diverse, impairment of intestinal barrier function, dysbiosis. and mucosal micro-inflammation are being increasingly recognized as underlying phenomena characterizing a variety of chronic diarrheal diseases. In addition to current pharmacological therapies, there is growing interest in alternative products such as mucoprotectants, which form a mucoadhesive film over the epithelium to reduce and protect against the development of altered intestinal permeability, dysbiosis, and mucosal micro-inflammation. This manuscript focuses on chronic diarrhea in adults, and we will review recent evidence on the ability of these natural compounds to improve symptoms associated with chronic diarrhea and to exert protective effects for the intestinal barrier., Supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad, Ajuts per a la contractació de personal investigador FI—Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, The Swedish Research Council and The European Commision: FIS LOBO 2019? (BL); FI20/00256 (MA-B). PI17/0190 (JS); PI15/00301 (CA-C); CIBERehd CB06/04/0021 (JS & CA-C); dnr 2019–00653 (J-PGM); 2020FI_B1 00127, 2019FI_B 00817 (MA-B); GA No:848228 (JS, CA-C, EE, AMG-C, BL).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition

  • Rodiño Janeiro, Bruno Kotska
  • Khannous, Olfat
  • Pigrau Pastor, Marc
  • Willis, Jesse R.
  • Pardo Camacho, Cristina
  • Albert Bayo, Mercé
  • Martínez Martínez, Cristina
  • lobo, beatriz
  • Santos, Javier
  • Salvo Romero, Eloisa
  • Nieto Ruiz, Adoración
  • Expósito , Elba
  • Fortea, Marina
  • González Castro, Ana Maria
  • Guagnozzi, Danila
  • Vicario Perez, Maria
  • Alonso Cotoner, Carmen
Irritable bowel syndrome; Small intestine microbiota; Stress, Síndrome del intestino irritable; Microbiota del intestino delgado; Estrés, Síndrome de l'intestí irritable; Microbiota de l'intestí prim; Estrès, Background/aims: Digestive disorders of gut-brain interaction (DGBI) are very common, predominant in females, and usually associated with intestinal barrier dysfunction, dysbiosis, and stress. We previously found that females have increased susceptibility to intestinal barrier dysfunction in response to acute stress. However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction. Methods: Jejunal biopsies were obtained at baseline and 90 min after cold pain or sham stress. Autonomic (blood pressure and heart rate), hormonal (plasma cortisol and adrenocorticotropic hormone) and psychological (Subjective Stress Rating Scale) responses to cold pain and sham stress were monitored. Microbial DNA from the biopsies was analyzed using a 16S metabarcoding approach before and after cold pain stress and sham stress. Differences in diversity and relative abundance of microbial taxa were examined. Results: Cold pain stress was associated with a significant decrease in alpha diversity (P = 0.015), which was more pronounced in females, along with significant sex differences in the abundance of specific taxa and the overall microbiota composition. Microbiota alterations significantly correlated with changes in psychological responses, hormones, and gene expression in the intestinal mucosal. Cold pain stress was also associated with activation of autonomic, hormonal and psychological response, with no differences between sexes. Conclusions: Acute stress elicits rapid alterations in bacterial composition in the jejunum of healthy subjects and these changes are more pronounced in females. Our results may contribute to the understanding of female predominance in DGBI., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), y de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad y Ministerio de Ciencia e Innovación: EII2011-0035, CD15/00010 and MV17-00043 (BR-J); CM10/00155 (MP); FI12/00254 (ES-R); FI20/00256 (MA-B); CP18/00116 (CM); PI19/01643 (BL); PI16/00583, PI19/01643 and CPII16/00031 (MV); PI17/0190 (JS); INB Grant PT17/0009/0023 (TG); PI15/00301 (CA-C); CIBEREHD CB06/04/0021 (AG-C, DG, BL, MV, JS, CA-C); CIBERINFEC CB21/13/00061 (TG). Vall d'Hebron Institut de Recerca, Programa de becas predoctorales Amics de Vall d'Hebron: PRED-VHIR-2014-018 (MF), PRED-VHIR-2016-53 (CP-C). Ajuts per a la contractació de personal investigador FI, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya: 2020FI_B1 00127 & 2019FI_B 00817 (MA-B), SGR423 (TG). Formación de profesorado universitario (FPU) program from the Spanish Ministerio de Universidades: FPU2020-02907 (OK-L). European Union's Horizon 2020 research and innovation program: ERC-2016-724173 (TG). Gordon and Betty Moore Foundation: GBMF9742 (TG).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Present and Future Therapeutic Approaches to Barrier Dysfunction

  • Albert Bayo, Merce
  • Abril-Gil, Mar
  • Serra Ruiz, Xavier
  • Henao Paez, Alejandro
  • Exposito Fernandez, Elba
  • Gonzalez Castro, Ana Maria
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Guagnozzi, Danila
  • Fortea, Marina
  • Alonso Cotoner, Carmen
  • Ganda Mall, John-Peter
Permeabilidad intestinal; Nutrientes; Prebióticos, Intestinal permeability; Nutrients; Prebiotics, Permeabilitat intestinal; Nutrients; Prebiòtics, There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected., This work was supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad, Ajuts per a la contractació de personal investigador FI–Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya; The Swedish Research Council, and the European Commision. PI19/0164 (BL), FI20/00256 and 2020FI_B1 00127, 2019FI_B 00817 (MA-B); PI17/0190 (JS); CIBERehd CB06/04/0021 (JS and CA-C); dnr 2019-00653 (JP-GM); GA no:848228 (JS, CA-C, EE, AG-C, and BL). MF received support from FWO (Fonds Wetenschappelijk Onderzoek) grant G.093818 to P. Vanden Berghe, KU Leuven.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction

  • Rodiño Janeiro, Bruno Kotska
  • Albert Bayo, Merce
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Farre, Ricard
  • Martínez, Cristina
  • Vicario Perez, Maria
  • Salvo Romero, Eloisa
Disorders of brain-gut interaction; Intestinal eosinophils; Neuro-immune interaction, Trastorns de la interacció cervell-intestí; Eosinòfils intestinals; Interacció neuroimmune, Trastornos de la interacción cerebro-intestino; Eosinófilos intestinales; Interacción neuroinmune, Eosinophils are innate immune granulocytes actively involved in defensive responses and in local and systemic inflammatory processes. Beyond these effector roles, eosinophils are fundamental to maintaining homeostasis in the tissues they reside. Gastrointestinal eosinophils modulate barrier function and mucosal immunity and promote tissue development through their direct communication with almost every cellular component. This is possible thanks to the variety of receptors they express and the bioactive molecules they store and release, including cytotoxic proteins, cytokines, growth factors, and neuropeptides and neurotrophines. A growing body of evidence points to the eosinophil as a key neuro-immune player in the regulation of gastrointestinal function, with potential implications in pathophysiological processes. Eosinophil–neuron interactions are facilitated by chemotaxis and adhesion molecules, and the mediators released may have excitatory or inhibitory effects on each cell type, with physiological consequences dependent on the type of innervation involved. Of special interest are the disorders of the brain–gut interaction (DBGIs), mainly functional dyspepsia (FD) and irritable bowel syndrome (IBS), in which mucosal eosinophilia and eosinophil activation have been identified. In this review, we summarize the main roles of gastrointestinal eosinophils in supporting gut homeostasis and the evidence available on eosinophil–neuron interactions to bring new insights that support the fundamental role of this neuro-immune crosstalk in maintaining gut health and contributing to the pathophysiology of DBGIs., This study was funded in part by the Fondo Europeo de Desarrollo Regional (FEDER), the Fondo de Investigación Sanitaria, the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), the Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, and the Ministerio de Economía y Competitividad: FI12/00254 (E.S-R.), CD15/00010 (B.K.R.-J.), FI20/00256 (M.A-B.), PI19/01643 (B.L.), PI17/0190 (J.S.), CP18/00116 (C.M), CPII16/00031 and PI19/01643 (M.V.), CIBEREHD CB06/04/0021 (J.S., R.F., M.V.).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Eosinophils in the Gastrointestinal Tract, Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction

  • Salvo-Romero, Eloísa
  • Rodiño-Janeiro, Bruno K.|||0000-0002-0633-6774
  • Albert-Bayo, Mercé|||0000-0002-9726-8083
  • Lobo Álvarez, Beatriz|||0000-0003-3391-7125
  • Santos, Javier|||0000-0002-4798-5033
  • Farré, Ricard|||0000-0001-7158-171X
  • Martínez, Cristina|||0000-0002-9368-1356
  • Vicario Perez, Maria|||0000-0001-9622-3185
Eosinophils are innate immune granulocytes actively involved in defensive responses and in local and systemic inflammatory processes. Beyond these effector roles, eosinophils are fundamental to maintaining homeostasis in the tissues they reside. Gastrointestinal eosinophils modulate barrier function and mucosal immunity and promote tissue development through their direct communication with almost every cellular component. This is possible thanks to the variety of receptors they express and the bioactive molecules they store and release, including cytotoxic proteins, cytokines, growth factors, and neuropeptides and neurotrophines. A growing body of evidence points to the eosinophil as a key neuro-immune player in the regulation of gastrointestinal function, with potential implications in pathophysiological processes. Eosinophil-neuron interactions are facilitated by chemotaxis and adhesion molecules, and the mediators released may have excitatory or inhibitory effects on each cell type, with physiological consequences dependent on the type of innervation involved. Of special interest are the disorders of the brain-gut interaction (DBGIs), mainly functional dyspepsia (FD) and irritable bowel syndrome (IBS), in which mucosal eosinophilia and eosinophil activation have been identified. In this review, we summarize the main roles of gastrointestinal eosinophils in supporting gut homeostasis and the evidence available on eosinophil-neuron interactions to bring new insights that support the fundamental role of this neuro-immune crosstalk in maintaining gut health and contributing to the pathophysiology of DBGIs.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Present and Future Therapeutic Approaches to Barrier Dysfunction

  • Albert Bayo, Merce
  • Abril-Gil, Mar
  • Serra Ruiz, Xavier
  • Henao Paez, Alejandro
  • Exposito Fernandez, Elba
  • Gonzalez Castro, Ana Maria
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Guagnozzi, Danila
  • Fortea, Marina
  • Alonso Cotoner, Carmen
  • Ganda Mall, John-Peter
Permeabilidad intestinal; Nutrientes; Prebióticos, Intestinal permeability; Nutrients; Prebiotics, Permeabilitat intestinal; Nutrients; Prebiòtics, There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected., This work was supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad, Ajuts per a la contractació de personal investigador FI–Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya; The Swedish Research Council, and the European Commision. PI19/0164 (BL), FI20/00256 and 2020FI_B1 00127, 2019FI_B 00817 (MA-B); PI17/0190 (JS); CIBERehd CB06/04/0021 (JS and CA-C); dnr 2019-00653 (JP-GM); GA no:848228 (JS, CA-C, EE, AG-C, and BL). MF received support from FWO (Fonds Wetenschappelijk Onderzoek) grant G.093818 to P. Vanden Berghe, KU Leuven.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Acute stress triggers sex-dependent rapid alterations in the human small intestine microbiota composition

  • Rodiño Janeiro, Bruno Kotska
  • Khannous, Olfat
  • Pigrau Pastor, Marc
  • Willis, Jesse R.
  • Pardo Camacho, Cristina
  • Albert Bayo, Mercé
  • Martínez Martínez, Cristina
  • lobo, beatriz
  • Santos, Javier
  • Salvo Romero, Eloisa
  • Nieto Ruiz, Adoración
  • Expósito , Elba
  • Fortea, Marina
  • González Castro, Ana Maria
  • Guagnozzi, Danila
  • Vicario Perez, Maria
  • Alonso Cotoner, Carmen
Irritable bowel syndrome; Small intestine microbiota; Stress, Síndrome del intestino irritable; Microbiota del intestino delgado; Estrés, Síndrome de l'intestí irritable; Microbiota de l'intestí prim; Estrès, Background/aims: Digestive disorders of gut-brain interaction (DGBI) are very common, predominant in females, and usually associated with intestinal barrier dysfunction, dysbiosis, and stress. We previously found that females have increased susceptibility to intestinal barrier dysfunction in response to acute stress. However, whether this is associated with changes in the small bowel microbiota remains unknown. We have evaluated changes in the small intestinal microbiota in response to acute stress to better understand stress-induced intestinal barrier dysfunction. Methods: Jejunal biopsies were obtained at baseline and 90 min after cold pain or sham stress. Autonomic (blood pressure and heart rate), hormonal (plasma cortisol and adrenocorticotropic hormone) and psychological (Subjective Stress Rating Scale) responses to cold pain and sham stress were monitored. Microbial DNA from the biopsies was analyzed using a 16S metabarcoding approach before and after cold pain stress and sham stress. Differences in diversity and relative abundance of microbial taxa were examined. Results: Cold pain stress was associated with a significant decrease in alpha diversity (P = 0.015), which was more pronounced in females, along with significant sex differences in the abundance of specific taxa and the overall microbiota composition. Microbiota alterations significantly correlated with changes in psychological responses, hormones, and gene expression in the intestinal mucosal. Cold pain stress was also associated with activation of autonomic, hormonal and psychological response, with no differences between sexes. Conclusions: Acute stress elicits rapid alterations in bacterial composition in the jejunum of healthy subjects and these changes are more pronounced in females. Our results may contribute to the understanding of female predominance in DGBI., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), y de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad y Ministerio de Ciencia e Innovación: EII2011-0035, CD15/00010 and MV17-00043 (BR-J); CM10/00155 (MP); FI12/00254 (ES-R); FI20/00256 (MA-B); CP18/00116 (CM); PI19/01643 (BL); PI16/00583, PI19/01643 and CPII16/00031 (MV); PI17/0190 (JS); INB Grant PT17/0009/0023 (TG); PI15/00301 (CA-C); CIBEREHD CB06/04/0021 (AG-C, DG, BL, MV, JS, CA-C); CIBERINFEC CB21/13/00061 (TG). Vall d'Hebron Institut de Recerca, Programa de becas predoctorales Amics de Vall d'Hebron: PRED-VHIR-2014-018 (MF), PRED-VHIR-2016-53 (CP-C). Ajuts per a la contractació de personal investigador FI, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya: 2020FI_B1 00127 & 2019FI_B 00817 (MA-B), SGR423 (TG). Formación de profesorado universitario (FPU) program from the Spanish Ministerio de Universidades: FPU2020-02907 (OK-L). European Union's Horizon 2020 research and innovation program: ERC-2016-724173 (TG). Gordon and Betty Moore Foundation: GBMF9742 (TG).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Eosinophils in the Gastrointestinal Tract: Key Contributors to Neuro-Immune Crosstalk and Potential Implications in Disorders of Brain-Gut Interaction

  • Rodiño Janeiro, Bruno Kotska
  • Albert Bayo, Merce
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Farre, Ricard
  • Martínez, Cristina
  • Vicario Perez, Maria
  • Salvo Romero, Eloisa
Disorders of brain-gut interaction; Intestinal eosinophils; Neuro-immune interaction, Trastorns de la interacció cervell-intestí; Eosinòfils intestinals; Interacció neuroimmune, Trastornos de la interacción cerebro-intestino; Eosinófilos intestinales; Interacción neuroinmune, Eosinophils are innate immune granulocytes actively involved in defensive responses and in local and systemic inflammatory processes. Beyond these effector roles, eosinophils are fundamental to maintaining homeostasis in the tissues they reside. Gastrointestinal eosinophils modulate barrier function and mucosal immunity and promote tissue development through their direct communication with almost every cellular component. This is possible thanks to the variety of receptors they express and the bioactive molecules they store and release, including cytotoxic proteins, cytokines, growth factors, and neuropeptides and neurotrophines. A growing body of evidence points to the eosinophil as a key neuro-immune player in the regulation of gastrointestinal function, with potential implications in pathophysiological processes. Eosinophil–neuron interactions are facilitated by chemotaxis and adhesion molecules, and the mediators released may have excitatory or inhibitory effects on each cell type, with physiological consequences dependent on the type of innervation involved. Of special interest are the disorders of the brain–gut interaction (DBGIs), mainly functional dyspepsia (FD) and irritable bowel syndrome (IBS), in which mucosal eosinophilia and eosinophil activation have been identified. In this review, we summarize the main roles of gastrointestinal eosinophils in supporting gut homeostasis and the evidence available on eosinophil–neuron interactions to bring new insights that support the fundamental role of this neuro-immune crosstalk in maintaining gut health and contributing to the pathophysiology of DBGIs., This study was funded in part by the Fondo Europeo de Desarrollo Regional (FEDER), the Fondo de Investigación Sanitaria, the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), the Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, and the Ministerio de Economía y Competitividad: FI12/00254 (E.S-R.), CD15/00010 (B.K.R.-J.), FI20/00256 (M.A-B.), PI19/01643 (B.L.), PI17/0190 (J.S.), CP18/00116 (C.M), CPII16/00031 and PI19/01643 (M.V.), CIBEREHD CB06/04/0021 (J.S., R.F., M.V.).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults

  • Abril Gil, Maria del Mar
  • Albert Bayo, Merce
  • Exposito Fernandez, Elba
  • Gonzalez Castro, Ana Maria
  • Lobo Alvarez, Beatriz
  • Santos Vicente, Fco Javier
  • Alonso Cotoner, Carmen
  • Ganda Mall, John-Peter
Chronic diarrhea; Mucoprotectans; Mucus, Diarrea crónica; Mucoprotectores; Moco, Diarrea crònica, Mucoprotectors; Moc, Chronic diarrhea is a frequent presenting symptom, both in primary care medicine and in specialized gastroenterology units. It is estimated that more than 5% of the global population suffers from chronic diarrhea. and that about 40% of these subjects are older than 60 years. The clinician is frequently faced with the need to decide which is the best therapeutic approach for these patients. While the origin of chronic diarrhea is diverse, impairment of intestinal barrier function, dysbiosis. and mucosal micro-inflammation are being increasingly recognized as underlying phenomena characterizing a variety of chronic diarrheal diseases. In addition to current pharmacological therapies, there is growing interest in alternative products such as mucoprotectants, which form a mucoadhesive film over the epithelium to reduce and protect against the development of altered intestinal permeability, dysbiosis, and mucosal micro-inflammation. This manuscript focuses on chronic diarrhea in adults, and we will review recent evidence on the ability of these natural compounds to improve symptoms associated with chronic diarrhea and to exert protective effects for the intestinal barrier., Supported in part by Fondo Europeo de Desarrollo Regional (FEDER), Fondo de Investigación Sanitaria and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria, Ministerio de Economía y Competitividad, Ajuts per a la contractació de personal investigador FI—Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya, The Swedish Research Council and The European Commision: FIS LOBO 2019? (BL); FI20/00256 (MA-B). PI17/0190 (JS); PI15/00301 (CA-C); CIBERehd CB06/04/0021 (JS & CA-C); dnr 2019–00653 (J-PGM); 2020FI_B1 00127, 2019FI_B 00817 (MA-B); GA No:848228 (JS, CA-C, EE, AMG-C, BL).